Brian Cunniff

Brian Cunniff

University of Vermont

H-index: 13

North America-United States

About Brian Cunniff

Brian Cunniff, With an exceptional h-index of 13 and a recent h-index of 13 (since 2020), a distinguished researcher at University of Vermont, specializes in the field of Mitochondrial Biology, Redox Biology, Cell Migration, Trafficking.

His recent articles reflect a diverse array of research interests and contributions to the field:

SLC7A11 modulates sensitivity to the first-in-class mitochondrial peroxiredoxin 3 inhibitor thiostrepton (RSO-021) via a ferroptosis independent pathway

First-in-class peroxiredoxin 3 (PRX3) inhibitor RSO-021 triggers mesenchymal-to-epithelial transition in mesothelioma

ROS production by mitochondria: function or dysfunction?

61 The first-in-class peroxiredoxin 3 (PRX3) inhibitor RSO-021 modulates the mesenchymal and immune phenotype in mesothelioma

Abstract B022: Effects of RSO-021 on cytokine profiles of malignant pleural effusions from patients enrolled in the MITOPE phase 1/2 clinical trial

Hydrogen sulfide induces long-term changes in mitochondrial energy metabolism

MA17. 11 Spatial Transformation in Mesothelioma Involves a Hypoxia-TGF Beta-EMT axis that is Reversible via PRX3 Inhibition

Deletion of Miro1 in airway club cells potentiates allergic asthma phenotypes

Brian Cunniff Information

University

Position

___

Citations(all)

1272

Citations(since 2020)

999

Cited By

728

hIndex(all)

13

hIndex(since 2020)

13

i10Index(all)

14

i10Index(since 2020)

14

Email

University Profile Page

Google Scholar

Brian Cunniff Skills & Research Interests

Mitochondrial Biology

Redox Biology

Cell Migration

Trafficking

Top articles of Brian Cunniff

Title

Journal

Author(s)

Publication Date

SLC7A11 modulates sensitivity to the first-in-class mitochondrial peroxiredoxin 3 inhibitor thiostrepton (RSO-021) via a ferroptosis independent pathway

Cancer Research

Terri Messier

Victoria Gibson

Aleksandra Bzura

Joanna Dzialo

Charlotte Poile

...

2024/3/22

First-in-class peroxiredoxin 3 (PRX3) inhibitor RSO-021 triggers mesenchymal-to-epithelial transition in mesothelioma

Cancer Research

Terri Messier

Victoria Gibson

David J Seward

Essa Y Baitei

Peter Wells Jordan

...

2024/3/22

ROS production by mitochondria: function or dysfunction?

Flavio R Palma

Benjamin N Gantner

Marcelo J Sakiyama

Cezar Kayzuka

Sanjeev Shukla

...

2024/1/29

61 The first-in-class peroxiredoxin 3 (PRX3) inhibitor RSO-021 modulates the mesenchymal and immune phenotype in mesothelioma

Lung Cancer

Brian Cunniff

Terri Messier

Victoria Gibson

David Seward

Essa Baitei

...

2024/4/1

Abstract B022: Effects of RSO-021 on cytokine profiles of malignant pleural effusions from patients enrolled in the MITOPE phase 1/2 clinical trial

Molecular Cancer Therapeutics

Terri Messier

Molly Scotland

George Naumov

Sean Dulloo

Dean Fennell

...

2023/12/1

Hydrogen sulfide induces long-term changes in mitochondrial energy metabolism

Journal of Biological Chemistry

David Hanna

Brian Cunniff

Ruma Banerjee

2023/1/1

MA17. 11 Spatial Transformation in Mesothelioma Involves a Hypoxia-TGF Beta-EMT axis that is Reversible via PRX3 Inhibition

Journal of Thoracic Oncology

M Zhang

T Messier

A Nakas

P Wells-Jordan

C Poile

...

2023/11/1

Deletion of Miro1 in airway club cells potentiates allergic asthma phenotypes

Frontiers in Allergy

Sierra Bruno

Amelia Lamberty

Margaret McCoy

Zoe Mark

Nirav Daphtary

...

2023/6/12

The role of miro1-mediated mitochondrial positioning in the development and metastasis of breast cancer

Cancer Research

Randi Gravelle

Margaret McCoy

Nathaniel Shannon

Martin Chang

Brian Cunniff

2023/4/4

Effects of RSO-021 on cytokine profiles of malignant pleural effusions from patients enrolled in the MITOPE phase 1/2 clinical trial

Terri Messier

Molly Scotland

George Naumov

Sean Dulloo

Dean Fennell

...

2023/12/1

Characterization of immune cell phenotypes in patient derived malignant pleural effusion treated with thiostrepton

Cancer Research

Terri Messier

Roxana Del Rio Guerra

George Naumov

Brian Cunniff

2023/4/4

Abstract C027: RSO-021, a first-in-class covalent inhibitor of mitochondrial PRX3: From bench to bedside

Dean A Fennell

Sean Dulloo

Peter Szlosarek

Fiona Thistlethwaite

Simon Lord

...

2023/12/1

WR1065 conjugated to thiol-PEG polymers as novel anticancer prodrugs: broad spectrum efficacy, synergism, and drug resistance reversal

Frontiers in Oncology

Dale M Walker

Tsvetelina I Lazarova

Steven W Riesinger

Miriam C Poirier

Terri Messier

...

2023

Cancer therapeutic compositions and methods

2022/3/10

The subcellular architecture of mitochondria in driving cellular processes

Frontiers in Cell and Developmental Biology

Brian Cunniff

Jyoti K Jaiswal

2022/8/26

Miro1-mediated mitochondrial positioning supports subcellular redox status

Free Radical Biology and Medicine

Nathaniel Shannon

Brian Cunniff

2022/2/20

Mitochondrial trafficking and redox/phosphorylation signaling supporting cell migration phenotypes

Nathaniel Shannon

Randi Gravelle

Brian Cunniff

2022/7/22

SIRT3 supports anchorage-independent survival of ovarian cancer cells by regulating mitochondrial redox signaling

Free Radical Biology and Medicine

Priscilla Tang

Yeon Kim

Piyushi Gupta Vallur

Amal Elhaw

Brian Cunniff

...

2022/11/1

Reactive oxygen species in the progression and treatment of malignant mesothelioma

Ava Cote

Terri Messier

Brian Cunniff

2022

182P Therapeutic activity of thiostrepton in patient-derived malignant pleural effusions

Annals of Oncology

B Cunniff

T Messier

R del Rio-Guerra

A Kopecky

G Scriver

...

2022/4/1

See List of Professors in Brian Cunniff University(University of Vermont)